Drug Search Results
More Filters [+]

Duloxetine

Alternative Names: duloxetine, cymbalta, ly-248686, ly 248686, ly248686, duloxetina, drizalma sprinkle, yentreve
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Duloxetine is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Duloxetine-(Cymbalta))

Mechanisms of Action: SSR Inhibitor,NRI Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Generalized anxiety disorder | Depressive Disorder | Depressive Disorder, Major | Chronic Pain | Pain Unspecified | Fibromyalgia | Musculoskeletal Pain | Myalgia

Known Adverse Events: Hyperhidrosis | Constipation | Diarrhea

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duloxetine

Countries in Clinic: Australia, China, Hong Kong, New Zealand, Unknown Location

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Depressive Disorder|Vision Disorders

Phase 2: Depressive Disorder, Major

Phase 1: Dermatitis, Atopic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-001599-46

P3

Active, not recruiting

Vision Disorders

2019-10-11

2006-7041-83/hah

P1

Not yet recruiting

Dermatitis, Atopic

2019-07-15

2017-000211-16

P2

Active, not recruiting

Depressive Disorder, Major

2016-07-15

CTR20200374

P3

Recruiting

Depressive Disorder

None

Recent News Events